Drugs / GLM101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06657859 | Sep 2024 → Sep 2029 expected | PMM2-congenital disorder of glycosylation | Glycomine, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05549219 | Nov 2022 → Nov 2025 | PMM2-congenital disorder of glycosylation | Glycomine, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06892288 | Jul 2025 → Sep 2026 overdue | PMM2-congenital disorder of glycosylation | Glycomine, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-09-18 | Glycomine, Inc. | Regulatory Glycomine Receives FDA Fast Track Designation for GLM101 for the Treatment of PMM2-CDG glycomine.com ↗
the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for GLM101 |
| 2024-03-04 | Glycomine, Inc. | Results Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG glycomine.com ↗
The findings highlight the potential for clinically meaningful benefit with a notable improvement in the International Co-operative Ataxia Rating Scale (ICARS) score in four adult patients in the 30 mg/kg cohort, with an average improvement of 12 points after 12 weeks (n=4) of treatment. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLM101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05549219 ↗ |
| Route | Intravenous | “GLM101 IV Infusion” NCT05549219 ↗ |